JPS5942653B2 - Gallstone dissolver - Google Patents

Gallstone dissolver

Info

Publication number
JPS5942653B2
JPS5942653B2 JP54038873A JP3887379A JPS5942653B2 JP S5942653 B2 JPS5942653 B2 JP S5942653B2 JP 54038873 A JP54038873 A JP 54038873A JP 3887379 A JP3887379 A JP 3887379A JP S5942653 B2 JPS5942653 B2 JP S5942653B2
Authority
JP
Japan
Prior art keywords
gallstone
dog
oil
bean oil
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54038873A
Other languages
Japanese (ja)
Other versions
JPS55130919A (en
Inventor
敏廣 林
正彦 大木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morishita Pharmaceuticals Co Ltd
Original Assignee
Morishita Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morishita Pharmaceuticals Co Ltd filed Critical Morishita Pharmaceuticals Co Ltd
Priority to JP54038873A priority Critical patent/JPS5942653B2/en
Publication of JPS55130919A publication Critical patent/JPS55130919A/en
Publication of JPS5942653B2 publication Critical patent/JPS5942653B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Description

【発明の詳細な説明】 本発明は犬豆油不ケン化物を主成分とする胆石溶解剤に
関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a gallstone dissolving agent containing an unsaponifiable product of dog bean oil as a main component.

胆石症患者の治療としては十二指腸ゾンデ法、排胆剤の
投与等が行なわれるが胆石を完全に溶解する薬剤は未だ
知られていない。
Treatments for patients with cholelithiasis include the duodenal probe method and the administration of anticholinergic drugs, but no drug that completely dissolves gallstones is known yet.

本発明者らは鋭意研究を行なった結果、大豆油の脱臭工
程中に得られる留出物をエステル化し分子蒸留によって
精製された犬豆油不ケン化物が著しい胆石形成阻止作用
を有しているとの知見を得本剤が胆石溶解剤として利用
できることを見い出した。
As a result of intensive research, the present inventors have found that unsaponifiable dog bean oil, which is obtained by esterifying the distillate obtained during the deodorization process of soybean oil and purified by molecular distillation, has a remarkable effect on inhibiting gallstone formation. We obtained this knowledge and discovered that this drug can be used as a gallstone dissolving agent.

本発明に係る犬豆油不ケン化物は、特異な臭いを有しわ
ずかに甘味を有する半固体状で粘稠な油状物質である。
The unsaponifiable product of dog bean oil according to the present invention is a semisolid, viscous oily substance that has a unique odor and a slightly sweet taste.

また、成分としては、植物ステロール類(β−シトステ
ロール、スチグマステロール、カンペステロール)40
〜50’%、トコフェロール類(α−2β−2δ−トコ
フェロール)18〜22%の外に高級不飽和胎胞酸(ラ
ウリル酸、ミリスチン酸、パルミチン酸、リノール酸等
)が約30%含まれている。
In addition, as an ingredient, plant sterols (β-sitosterol, stigmasterol, campesterol) 40
Contains ~50%, tocopherols (α-2β-2δ-tocopherol) 18-22%, and approximately 30% higher unsaturated fetal acids (lauric acid, myristic acid, palmitic acid, linoleic acid, etc.). There is.

また、溶剤に対する溶解性はクロロホルム1.1g/m
l、エーテル0.597m1、アセトン0.2 X I
F297mlエタノール0.2xlO−397mlで
水にほぼさんど溶けない。
Also, the solubility in solvent is chloroform 1.1g/m
l, ether 0.597ml, acetone 0.2X I
F297ml ethanol 0.2xlO-397ml is almost insoluble in water.

以下、本発明について詳細に説明する。The present invention will be explained in detail below.

〔犬豆油不ケン化物の精製法〕[Method for refining dog bean oil unsaponifiables]

大豆原油をガードラー型脱臭装置で約230℃、2〜3
miHg減圧下、1時間に5%の水蒸気を吹き込むと、
脱臭油トラツプから植物ステロール類(25〜30%)
、トコフェロール類(14〜18%)および高級不飽和
脂肪酸(25〜30%)等を含む大豆油脱臭留出物を得
る。
Soybean crude oil is heated to approximately 230℃ using a Girdler type deodorizer for 2 to 3 hours.
When 5% steam is blown in for 1 hour under miHg vacuum,
Plant sterols (25-30%) from deodorized oil traps
A soybean oil deodorized distillate containing tocopherols (14-18%), higher unsaturated fatty acids (25-30%), etc. is obtained.

この脱臭留出物174(B9にメタノール3000gと
濃硫酸34gとを混合し68℃で3〜4時間還流した後
、過剰のメタノールを減圧下留去し残渣の油状物を80
〜100°Cに保ちながら温水5kgで洗浄し残渣に含
まれる硫酸を除去する。
This deodorized distillate 174 (B9) was mixed with 3000 g of methanol and 34 g of concentrated sulfuric acid, and after refluxing at 68°C for 3 to 4 hours, excess methanol was distilled off under reduced pressure and the residual oil was
Wash with 5 kg of warm water while maintaining the temperature at ~100°C to remove sulfuric acid contained in the residue.

油状物に含まれる水分を完全に留去した後20〜130
μHgの真空下、170〜190°Cの温度で分子蒸留
により生成した脂肪酸メチルを留去し目的の植物ステロ
ール類40〜50係、トコフェロール類18〜22係、
高級不飽和脂肪酸類的30%の犬豆油不ケン化物を釜残
法として得る。
20-130 after completely distilling off the water contained in the oil
Under a vacuum of μHg and at a temperature of 170 to 190°C, the fatty acid methyl produced by molecular distillation is distilled off to obtain the target plant sterols 40 to 50, tocopherols 18 to 22,
Unsaponifiable dog bean oil containing 30% of higher unsaturated fatty acids is obtained as a pot residue method.

各条件での実際例を表1に示す。Actual examples under each condition are shown in Table 1.

次に、成分の定量法を簡単に述べる。Next, a method for quantifying the components will be briefly described.

植物ステロール:試料を水酸化カリウムでケン化しジキ
トニンを反応させて生成したジギトニドの重量及びガス
クロマトグラムから得られたカンペステロール、スチグ
マステロール、β−シトステロールの相対比から植物ス
テロール量を求めた。
Plant sterols: The amount of plant sterols was determined from the weight of digitonide produced by saponifying the sample with potassium hydroxide and reacting with digitonin, and the relative ratio of campesterol, stigmasterol, and β-sitosterol obtained from the gas chromatogram.

トコフェロール:試料をクロロホルムに溶解し塩化第二
鉄、無水エタノール溶液を加え、更にα、d−ジピリジ
ルを加えて赤色の錯塩を生成させ波長520mμにおけ
る吸光度を測定しα−トコフェロールを標準液として各
々の吸光度から求めた。
Tocopherol: Dissolve the sample in chloroform, add ferric chloride and anhydrous ethanol solution, and further add α, d-dipyridyl to form a red complex salt. Measure the absorbance at a wavelength of 520 mμ. Using α-tocopherol as a standard solution, each Determined from absorbance.

高級脂肪酸:(ケン化価/中和価)X100(%)の式
から求めた。
Higher fatty acid: Determined from the formula (saponification value/neutralization value) x 100 (%).

但し、試料中の脂肪酸が常に一定組成であるとは限らな
いので便宜上、リノール酸の中和価を代用した。
However, since the fatty acids in the sample do not always have a constant composition, the neutralization value of linoleic acid was used as a substitute for convenience.

〔急性毒性試験〕[Acute toxicity test]

生後4週令で購入し1週間実験室で飼育したdd系マウ
ス(雌、雄)で体重12〜iBのものおよびWista
r系ラット(雌、雄)で体重60〜91のものを夫々5
匹一群として用いた。
DD mice (female, male) purchased at 4 weeks of age and kept in the laboratory for 1 week, weighing 12-iB and Wista.
5 R-strain rats (female, male) weighing 60-91 each
The animals were used as a group.

犬豆油不ケン化物はゴマ油に溶解し、マウスでは経口で
8.0g/ky、皮下注射で4.0g/kg、腹腔注射
で2.0g・7kgになる様に、また、ラットでは経口
で8.0g/kg、皮下注射で2.097kg、腹腔注
射で1.07に9投与した。
Unsaponifiable dog bean oil is dissolved in sesame oil and administered to mice at 8.0g/ky orally, 4.0g/kg by subcutaneous injection, 2.0g/7kg by intraperitoneal injection, and 8.0g/ky orally for rats. .0 g/kg, 2.097 kg by subcutaneous injection, 1.07 by intraperitoneal injection.

投与後72時間で生死を判定し引続き10日間観察した
Liveness or death was determined 72 hours after administration, and observation was continued for 10 days.

その結果、投与後72時間における判定ではいずれも生
存し、その後の10日間でも死亡したものが見られずL
D5oの算出は不可能であった。
As a result, 72 hours after administration, all of the animals were found to be alive, and no deaths were observed for the next 10 days.
Calculation of D5o was not possible.

また、投与後の中毒症状および行動については正常動物
群となんら違いは認められなかった。
Furthermore, no differences were observed between the toxic symptoms and behavior after administration compared to the normal animal group.

〔マウスの胆石症モデルに及ぼす影響〕[Effect on mouse cholelithiasis model]

マウスの胆石症モデルはコレステロールとコール酸を負
荷することによって作製できることがTepperma
nにより最初見い出され(Ame r −1can J
ournal of Physiology206
628.1964)、次いてFreyらによって確認さ
れている(American Journal o
fSurgery 115.75.1968)。
Tepperma has shown that a cholelithiasis model in mice can be created by loading them with cholesterol and cholic acid.
First discovered by n (Amer −1can J
our own of Physiology206
628.1964), then confirmed by Frey et al. (American Journal o
fSurgery 115.75.1968).

従って、この方法により犬豆油不ケン化物の胆石症への
効果を確認した。
Therefore, by this method, the effect of unsaponifiable dog bean oil on cholelithiasis was confirmed.

即ち、胆石形成飼料は日本タレア製CB−n粉末飼料に
1.2%のコレステロールおよび0.5%のコール酸を
混飼し調製した飼料で8週間飼育した。
That is, the gallstone-forming feed was prepared by mixing 1.2% cholesterol and 0.5% cholic acid with Nippon Talea's CB-n powder feed, and the animals were fed for 8 weeks.

一方、犬豆油不ケン化物は前記胆石形成飼料に各々1.
5係、2.9%、5.8%になるように添加し8週間自
由に摂取させた。
On the other hand, dog bean oil unsaponifiables are added to the gallstone-forming feed at 1% each.
5, 2.9%, and 5.8%, and allowed to ingest ad libitum for 8 weeks.

また、そ量水も自由に摂取させた。They were also allowed to drink water ad libitum.

各動物は8週間目に1夜絶食後頚部より放血致死させ開
腹して胆石の有無を観察した。
At 8 weeks, each animal was fasted for one night, then sacrificed by exsanguination from the neck, and the abdomen was opened to observe the presence or absence of gallstones.

胆石の確認は肉眼で観察した後、更に鏡拡大(40倍)
により行なった。
Confirm gallstones by observing with the naked eye and then using a mirror magnification (40x)
This was done by

なお、胆石形成飼料を用いないものを正常食群とした。In addition, the normal diet group was defined as one in which no gallstone-forming feed was used.

対照薬としてはchenodesoxycholic
ac−id (CDCAと略す)を用いた。
As a control drug, chenodesoxycholic
ac-id (abbreviated as CDCA) was used.

その結果を表2に示す。The results are shown in Table 2.

表2から明らかなように正常食群では胆石を認めなかっ
たが、胆石形成負群では金側に胆石形成が認められた。
As is clear from Table 2, no gallstones were observed in the normal diet group, but gallstone formation was observed on the gold side in the gallstone formation negative group.

犬豆油不ケン化物投与群では投与量の増加に従い胆石形
成率は顕著な減少を示し、5、8 %の濃度では胆石は
全く認められなかった。
In the dog bean oil unsaponifiables administration group, the gallstone formation rate significantly decreased as the dose increased, and no gallstones were observed at concentrations of 5 and 8%.

〔ハムスターの胆石症モデルに及ぼす影響〕胆石症ハム
スターの作製はDamらの方法(Acta Path
ologicaet Microbio−1ogica
5candinavica、30,236.195
2)に準じて行なった。
[Influence on hamster cholelithiasis model] Cholelithiasis hamsters were created using the method of Dam et al.
ologicaet Microbio-1logica
5candinavica, 30,236.195
2).

即ち、胆石形成負群はグルコース71.8%、カゼイン
20,0%、ビタミン0.5%、無機質5.0係、CM
C2,5%、塩化コリン0.2%をそれぞれ混飼した飼
料により6週間飼育した。
That is, the group with negative gallstone formation has glucose of 71.8%, casein of 20.0%, vitamins of 0.5%, minerals of 5.0%, and CM.
The rats were fed for 6 weeks with a mixture of 5% C2 and 0.2% choline chloride.

一方、犬豆油不ケン化物は前記胆石形成飼料に各々1条
、2%、4%になるように、また、CDCAは各々0.
001%、0.005係、0.01%になるように添加
した飼料で飼育した。
On the other hand, the unsaponifiables of dog bean oil were added to the gallstone-forming feed at 1%, 2%, and 4%, respectively, and the CDCA was added to 0.0%, respectively.
The animals were fed with feed containing 0.001%, 0.005%, and 0.01%.

なお、飼料は給飼器に入れ与え、水は自由に与えた。In addition, feed was provided in a feeder, and water was provided ad libitum.

各動物は実7験開始から6週間用に1夜絶食し、頚部よ
り放血致死させた後胆のう内の胆石を肉眼で観察した。
Each animal was fasted overnight for 6 weeks from the start of the experiment, and the animals were killed by exsanguination from the neck, and gallstones in the gallbladder were visually observed.

その結果を表3に示す。表中、薬物投与群の胆石形成率
は胆石形成負群を100%とした場合の百分率を示す。
The results are shown in Table 3. In the table, the gallstone formation rate in the drug administration group is expressed as a percentage when the gallstone formation negative group is taken as 100%.

表3から明らかな様に、正常食群では胆石は認められな
かったが、胆石形成負群では40例中の20例に胆石が
認められた。
As is clear from Table 3, no gallstones were observed in the normal diet group, but gallstones were observed in 20 out of 40 cases in the gallstone formation negative group.

一方、薬物投与群のうち犬豆油不ケン化物群では1%で
13例中3例、2%で16例中4例、4%で16例中1
例胆石が確認されたにすぎず、不法に於いても顕著な効
果を示した。
On the other hand, among the drug administration group, in the dog bean oil unsaponifiables group, 1% was 3 out of 13 cases, 2% was 4 out of 16 cases, and 4% was 1 out of 16 cases.
Only gallstones were confirmed, and it showed a remarkable effect even in illegal cases.

またCDCA投与群では顕著な効果は認められなかった
Further, no significant effect was observed in the CDCA administration group.

次に、水剤の投与量及び投与方法について述べる。Next, the dosage and administration method of the solution will be described.

水剤は、硬、軟カプセル剤として経口投与される。The solution is administered orally in the form of hard or soft capsules.

成人の治療に用いられる場合の有効量は通常1日当り犬
豆油不ケン化物として15〜1501n9/体重kgの
範囲が適当である。
When used for the treatment of adults, the effective amount is usually in the range of 15 to 1501 n9/kg body weight of dog bean oil unsaponifiables per day.

犬豆油不ケン化物を硬カプセル剤として製剤化する場合
、高純度無水ケイ酸を吸着基剤として用いクロロホルム
、クロロセン、メチレンクロライド等の有機溶媒を加え
て練合する方法(特公昭4.9−46899)に従って
顆粒化を行ない、1カプセル中犬豆油不ケン化物が20
0■含有するようにカプセルに充填した。
When formulating unsaponifiable dog bean oil as a hard capsule, a method is used in which high-purity silicic anhydride is used as an adsorption base and organic solvents such as chloroform, chlorocene, methylene chloride, etc. 46899), and the unsaponifiable matter of dog bean oil in one capsule is 20%.
Capsules were filled to contain 0.

また、軟カプセル剤とするにはゴマ油、ナタネ油、オリ
ーブ油、大豆油等の植物油を犬豆油不ケン化物1mg当
り0.20〜0.50m1用いて溶解したものを軟カプ
セルに充填した。
To prepare soft capsules, a vegetable oil such as sesame oil, rapeseed oil, olive oil, soybean oil, etc. is dissolved in 0.20 to 0.50 ml per 1 mg of dog bean oil unsaponifiable matter, and the solution is filled into soft capsules.

例えば1カプセル中に犬豆油不ケン化物が200TnJ
?含まれる様にする為に90m1のナタネ油を用いた。
For example, one capsule contains 200TnJ of dog bean oil unsaponifiables.
? 90 ml of rapeseed oil was used to achieve inclusion.

【図面の簡単な説明】[Brief explanation of drawings]

図1は大豆油不ケン化物の赤外線吸収スペクトルを示す
Figure 1 shows the infrared absorption spectrum of unsaponifiable soybean oil.

Claims (1)

【特許請求の範囲】[Claims] 1 犬豆油不ケン化物を主成分とする胆石溶解剤。1. A gallstone dissolving agent whose main ingredient is dog bean oil unsaponifiables.
JP54038873A 1979-03-30 1979-03-30 Gallstone dissolver Expired JPS5942653B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP54038873A JPS5942653B2 (en) 1979-03-30 1979-03-30 Gallstone dissolver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP54038873A JPS5942653B2 (en) 1979-03-30 1979-03-30 Gallstone dissolver

Publications (2)

Publication Number Publication Date
JPS55130919A JPS55130919A (en) 1980-10-11
JPS5942653B2 true JPS5942653B2 (en) 1984-10-16

Family

ID=12537322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54038873A Expired JPS5942653B2 (en) 1979-03-30 1979-03-30 Gallstone dissolver

Country Status (1)

Country Link
JP (1) JPS5942653B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647805A1 (en) * 1989-06-06 1990-12-07 Bugat Maurice Process for manufacture of fatty acid esters, corresponding isolated products and compositions for human or veterinary use containing them

Also Published As

Publication number Publication date
JPS55130919A (en) 1980-10-11

Similar Documents

Publication Publication Date Title
DE60013130T2 (en) CONJUGATES OF ASCORBIC ACID AND PHYTOSTEROLS OR PHYTOSTANOLS AND THEIR USE FOR THE TREATMENT OF VASCULAR DISEASES
US4083973A (en) Pharmaceutical preparation adapted for oral administration
AU2008252830B2 (en) Novel composition based on cholest-4-ene-3-one oxime
RO108220B1 (en) Pharmaceutical preparates for muscular cramps struggling against and preparation process therefor
HU176742B (en) Process for preparing pharmaceutical preparations containing new estradiol-17beta-estres with estrogen activity for oral application
US4260603A (en) Sterol glycoside with activity as prostaglandin synthetase inhibitor
JP3183664B2 (en) Metabolic inhibitors of cholesterol and bile acids
DE69901250T2 (en) 7.ALPHA.-METHYL 19-NORTESTOSTERONE UNDECANOAT WITH ANDROGENIC ACTIVITY
NZ189297A (en) Pgs inhibitor containing sterol glycosides
JPS63104917A (en) Oral administration composition
DE60026644T2 (en) Use of ferulic acid for the treatment of hypertension
JPH05194250A (en) Novel pharmaceutical composition derived from oxygen fraction of lipid extract of sabal serrulata and method for producing said composition
KR870001020B1 (en) Process for preparing silibinin derivatives
US3993756A (en) Antilipemic agent containing a soybean oil fraction
JPS5942653B2 (en) Gallstone dissolver
JPH05502457A (en) Kava kava extracts, their manufacturing process and uses
KR20130094490A (en) Improved pharmaceutical preparation containing yellow-popular bark extract as active ingredient
DE2723876C2 (en) 17β-esters of testosterone
FR2862224A1 (en) New organometallic strontium complexes, useful as high bioavailability strontium source for stimulating bone growth and hematopoiesis, obtained from strontium cation, sitosterol and glyceride
CN114173775A (en) Medicine composition of ledebouriella root lactone and its use
JPS5843385B2 (en) Medicinal ingredients of freshwater clam and its manufacturing method
EP0092073A1 (en) Magnesium salt of chenodeoxycholic acid and ursodeoxycholic acid, the process for its preparation, and therapeutic compositions which contain it as active principle
JPH06298645A (en) Agent for treating and preventing hyperlipemia
JP2001163772A (en) Anticataract agent
KR100273719B1 (en) An oil compositon for lowering high cholesterol level